Glutathione
In clinical developmentAlso known as 5-L-Glutamyl-L-cysteinylglycine, GLYCINE, L-.GAMMA.-GLUTAMYL-L-CYSTEINYL-, GSH, L-Glutathione+6 more
5-L-Glutamyl-L-cysteinylglycine, GLYCINE, L-.GAMMA.-GLUTAMYL-L-CYSTEINYL-, GSH, L-Glutathione, N-(N-gamma-L-Glutamyl-L-cysteinyl)glycine, Navstel, gamma-L-Glutamyl-L-cysteinyl-glycine, Glutathion, Glutathione-L, Glutathione-SH.
Recent clinical, regulatory, research and industry developments relating to this drug.
Adia MED of Winter Park LLC Autism Spectrum Disorder Research Study
Adia Med of Winter Park LLC Chronic Kidney Disease Research Study
Greater Atlanta Integrative Pediatrics Autism Spectrum Disorder Research Study
A Pilot Randomized Controlled Study of Combinatorial Gerotherapeutics for Healthspan Improvement
Redox regulation of the immune response.
Ferroptosis Mechanisms Involved in Neurodegenerative Diseases.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
A Pilot Randomized Controlled Study of Combinatorial Gerotherapeutics for Healthspan Improvement
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- International journal of molecular sciences2
- Biomolecules1
- Cellular & molecular immunology1
- Journal of Parkinson's disease1
- Molecules (Basel, Switzerland)1
- Nutrients1
- Ali A1
- Azam M1
- Banerji R1
- Barros PL1
- Bydlowski SP1
- Choi I1
- Cui YL1
- Cuperlovic-Culf M1
- ACS Medical College and Hospital1
- Brazilian Institute of Regenerative Medicine (BIRM)1
- Center for Neurodegenerative and Neuroimmunologic Diseases1
- Clinical Research1
- Deakin University1
- Digital Technologies Research Centre1
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 3 of the same disease areas as Glutathione in the shared literature.
Studied across 3 of the same disease areas as Glutathione in the shared literature.
Studied across 3 of the same disease areas as Glutathione in the shared literature.
Studied across the same disease area as Glutathione in the shared literature.
Studied across the same disease area as Glutathione in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials